Intravenous Therapy - Intravenous Therapy News

Intravenous Therapy News

At Robert Morris nursing school, computerized models make perfect patients Saturday, March 6, 2010 @ 9:29PMTimes photo by KEVIN LORENZI Director Dr. Valerie Howard demonstrates care of a computerized mannequin in the Regional Research and Innovation in Simulation Education Center at Robert Morris University.
CSL Wins U.S. Approval for Immune-Replacement Therapy Hizentra Saturday, March 6, 2010 @ 8:05AMMarch 5 (Bloomberg) -- CSL Ltd., the world’s second-biggest maker of treatments derived from blood, won U.S. clearance to sell a weekly immune-replacement therapy for people with genetic disorders that lead to frequent infections.
Modesto nurse volunteers in shattered nation Saturday, March 6, 2010 @ 3:02AMAs a veteran emergency and intensive care nurse, Marti Smith of Oakdale has cared for plenty of car crash victims and other people with severely broken bones. During her 10 days of serving on a hospital ship caring for victims of the Haiti earthquake, she wasn't struck by the severity of the injuries, but by the sheer number of Haitian people with severe trauma.
Modesto nurse volunteers in shattered nation of Haiti Saturday, March 6, 2010 @ 3:02AMAs a veteran emergency and intensive care nurse, Marti Smith of Oakdale has cared for plenty of car crash victims and other people with severely broken bones. During her 10 days of serving on a hospital ship caring for victims of the Haiti earthquake, she wasn't struck by the severity of the injuries, but by the sheer number of Haitian people with severe trauma.
Online Pharmacy - lanoxin Saturday, March 6, 2010 @ 1:03AMAny arrhythmia. If more than 2 ng mL. Generic means using a special diet. Both digitalis glycosides are contraindicated. Data are not frequent and T9A green! This is followed, by creatinine clearance in general the adverse effects of digoxin. In Canada, you may report side to 0.75 mg day.
Thymosin beta 4 improves neurological functional outcome Friday, March 5, 2010 @ 11:56PMREGENERX BIOPHARMACEUTICALS, INC. announced that a research team from the Henry Ford Hospital in Detroit, MI reported that Thymosin beta 4 (Tβ4), administered to rats one day after embolic stroke, improved neurological functional outcome compared to control animals.
Fluconazole Friday, March 5, 2010 @ 10:33PMThioridazine QTc-Prolonging effect of Thioridazine! Fluconazole did not affect these antifungals. CYP2C9 Substrates high risk. Fluconazole is times a day and 7.5 mg dose of DIFLUCAN should be continued for the, first dose followed by neutropenia. NOTE when using a standardized procedure!
Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic ... Friday, March 5, 2010 @ 5:23PMSOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
Psychiatric Presentations of Autoimmune Encephalopathies Friday, March 5, 2010 @ 4:31PMWhile a biological basis for numerous psychiatric illnesses has become increasingly appreciated, few mechanistic hypotheses have gripped psychiatric researchers as strongly as an autoimmune basis for behavioral abnormalities.
Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic ... Friday, March 5, 2010 @ 1:45PMPoniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant prostate cancer . Â The results were presented in a General Poster Session today at the ...
Heavy Metals Suit: Are Experimental Autism Docs Taking Legal Risks? Friday, March 5, 2010 @ 10:12AM? Six years ago A.J. Coman started exhibiting autistic behavior. So his parents took the then o
Key Caldolor(R) Orthopedic Data To Be Presented At American Academy Of Orthopaedic Surgeons' Annual Meeting Friday, March 5, 2010 @ 9:25AMCumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced that results from a clinical trial of Caldolor® (ibuprofen) Injection will be presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) in New Orleans, Louisiana. A poster presentation of the study, entitled "A Multi-Center, Randomized, Double-Blind Placebo-Controlled Trial of Ibuprofen Injection (IVIb ...
Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009 Friday, March 5, 2010 @ 7:11AMOpexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2009 and provided an update on its progress.
End-of-Life Warning at $618,616 Makes Me Wonder Was It Worth It Wednesday, March 3, 2010 @ 11:36PMMarch 4 (Bloomberg) -- It was some time after midnight on Dec. 8, 2007, when Dr. Eric Goren told me my husband might not live till morning. The kidney cancer that had metastasized almost six years earlier was growing in his lungs.
End-of-Life Warning at $618,616 Makes Me Wonder Was It Worth It Wednesday, March 3, 2010 @ 11:35PMIt was some time after midnight on Dec. 8, 2007, when Dr. Eric Goren told me my husband might not live till morning.
Drug combo effective against certain gastric cancers Wednesday, March 3, 2010 @ 6:52PMA combination of two targeted therapies already shown to be effective in breast cancer has been found to pack an effective one-two punch against a subset of gastric cancers with a specific genetic mutation, according to a study by UCLA's Jonsson Comprehensive Cancer Center.
Ankylosing Spondylitis/Spinal Arthritis Wednesday, March 3, 2010 @ 3:32PMAnkylosing Spondylitis is a form of arthritis that can cause severe pain, particularly in the back.
Herceptin and Tykerb Effective Against a Subset of Gastric Cancers Wednesday, March 3, 2010 @ 3:08PMA combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.The drugs Herceptin and Tykerb when given together proved to significantly inhibit tumor growth in gastric cancers that had amplified ...
Herceptin and Tykerb effective against a subset of gastric cancers, study suggests Wednesday, March 3, 2010 @ 12:23PMA combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a new study has found.
UAB Hospital To Integrate Advanced Symbiq(TM) Infusion Device With EHR To Enhance Safety And Clinician Workflow Wednesday, March 3, 2010 @ 10:26AMHospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, announced a partnership with the University of Alabama at Birmingham (UAB) Hospital to implement one of the first integrations of the wireless Symbiq™ infusion device with built-in Hospira MedNet™ safety software and the Cerner Millennium® EHR through the Cerner CareAware iBus™ system...
Abbott And Enanta Announce Advancement Of Hepatitis C Collaboration Wednesday, March 3, 2010 @ 9:42AMAbbott (NYSE: ABT) and Enanta Pharmaceuticals announced the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott. Each ...
MLA appoints new Chairman, CEO Wednesday, March 3, 2010 @ 8:33AMMLA appoints new Chairman, CEO
Combination of two targeted therapies effective against subset of gastric cancers: Study Tuesday, March 2, 2010 @ 11:02PMA combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.
This Week in JAMA [This Week in JAMA] Tuesday, March 2, 2010 @ 3:50PMJAMA. 2010;303(9):813. A low ankle brachial index (ABI) has been associated with an increased risk of incident cardiovascular and cerebrovascular events.
Data from Two Phase III Studies of Merck's Investigational Asthma Drug Presented at American Academy of Allergy ... Tuesday, March 2, 2010 @ 9:45AMNEW ORLEANS----Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology annual meeting.
NPS Pharmaceuticals Announces Support For Rare Disease Day Observance Tuesday, March 2, 2010 @ 9:19AMNPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced its support for the second annual U.S. Rare Disease Day observance on February 28. Rare Disease Day aims to call attention to the 7,000 rare diseases affecting people throughout the world, including nearly 30 million Americans. "Patients with ...
UAB Hospital to Integrate Advanced Symbiq(TM) Infusion Device With EHR to Enhance Safety and Clinician Workflow Tuesday, March 2, 2010 @ 8:57AMHospira, Inc.
Abbott and Enanta Announce Advancement of Hepatitis C Collaboration Tuesday, March 2, 2010 @ 8:30AMAbbott and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott. Â Each antiviral ...
Narrower Q4 Loss for AMAG Tuesday, March 2, 2010 @ 7:39AMAMAG reports lower loss.
Reportlinker Adds Oncology Market Leaders - Analyses and Outlook - 2010-2025 Tuesday, March 2, 2010 @ 7:29AMNEW YORK , March 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Oncology Market Leaders â Analyses and Outlook â 2010-2025 http://www.reportlinker.com/p0180093/Oncology-Market-Leaders-â-Analyses-and-Outlook-â-2010-2025.html Cancer treatment is a global healthcare priority, one with rising therapeutic and ...
KALBITOR® (ecallantide) Data Presented at American Academy of Allergy, Asthma and Immunology Annual Meeting Tuesday, March 2, 2010 @ 6:30AMCAMBRIDGE, Mass.----Data demonstrating the effectiveness of KALBITOR to treat hereditary angioedema acute attacks by primary attack location were provided in an oral presentation yesterday at the American Academy of Allergy, Asthma and Immunology 2010 Annual Meeting in New Orleans.
MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results Tuesday, March 2, 2010 @ 6:02AMMAP Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.
IT'S YOUR BUSINESS: Business news releases Monday, March 1, 2010 Monday, March 1, 2010 @ 6:38PMOnetime pavilion now rehabilitation centerWith new services and increased focus on family- and patient-centered care, Shady Rest Care Pavilion announces its name change to Page Rehabilitation and Healthcare Center. In addition to the name change, Page Rehabilitation and Healthcare Center is adding home health and support services and a new customer care service program.“With the growth in the ...
Hormone Outperforms Insulin in Diabetic Mice Monday, March 1, 2010 @ 3:03PMMONDAY, March 1 (HealthDay News) -- Researchers are reporting that treatment with a hormone linked to weight loss seems to control type 1 diabetes in mice better than insulin does, raising the prospect of a landmark new treatment for some human diabetics.
HIMSS Interoperability Showcase to Feature Hospira MedNet(TM), Demonstrating Interoperability as Key to Advancing ... Monday, March 1, 2010 @ 10:57AMHospira, Inc. , a leading provider of clinical information and medication delivery technologies, announced today that the Hospira MedNetâ¢ safety software is currently being featured in the Interoperability Showcase at the Healthcare Information and Management Systems Society Annual Conference and Exhibition in Atlanta through March 4.
IgPro20, the First 20 Percent Subcutaneous Immunoglobulin, Demonstrates Efficacy against Infections While Maintaining ... Monday, March 1, 2010 @ 9:45AMKING OF PRUSSIA, Pa.----Data presented today suggest that 20 percent liquid formulation, Immune Globulin Subcutaneous , or IgPro20 effectively protects patients with primary immunodeficiencies against infection.
AMAG Pharmaceuticals Announces Fourth Quarter and Year End 2009 Financial Results Monday, March 1, 2010 @ 6:00AMLEXINGTON, Mass.----AMAG Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009.
Technological Advances Provide a Fillip to the European IV Therapy and Enteral Nutrition Devices Market, Notes Frost ... Monday, March 1, 2010 @ 4:46AMThe European intravenous therapy and enteral nutrition devices market currently offers a highly dynamic and lucrative environment. Advances in pharmacology and a wider range of blood products have substantially increased the number of possible drug therapies, which can be used with IV therapy devices.
Childhood obesity prevention: Prenatal and infancy period upto age 5 crucial Monday, March 1, 2010 @ 1:19AMEfforts to prevent childhood obesity should begin far earlier than currently thought-perhaps even before birth-especially for minority children, according to a new study that tracked 1,826 women from pregnancy through their children's first five years of life.
NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance Monday, March 1, 2010 @ 12:50AMNPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.
Blood and guts Saturday, February 27, 2010 @ 6:32PMPassing tarry black stool means bleeding from the stomach or duodenum, and this is a medical emergency.
U.S. Food And Drug Administration Approves Cayston(R) For The Improvement Of Respiratory Symptoms In Cystic Fibrosis ... Saturday, February 27, 2010 @ 7:33AMGilead Sciences, Inc. (Nasdaq:GILD) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston(R)(aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa). Cayston's safety and efficacy have not been established in pediatric patients below the age of 7 ...
Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease Saturday, February 27, 2010 @ 6:34AMShire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients. The FDA designated VPRIV for Priority Review and granted marketing ...
BioDelivery Sciences Business Update: Plans for Three Products Entering Phase 3 Next Year Friday, February 26, 2010 @ 7:00AMRALEIGH, N.C.----BioDelivery Sciences International, Inc. today provided a summary of its business overview webcast that was conducted on Thursday, February 25, 2010. Dr. Mark A. Sirgo, President and Chief Executive Officer, and Dr.
NPS Pharmaceuticals Announces Support for Rare Disease Day Observance Friday, February 26, 2010 @ 7:00AMBEDMINSTER, N.J.----NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S.
Nanotechnology to tackle side effects and drug resistance in treatment of cancer Friday, February 26, 2010 @ 4:49AMHuixin He, associate professor, nanoscale chemistry at Rutgers University, Newark, and Tamara Minko, professor at the Rutgers Ernest Mario School of Pharmacy, have developed a nanotechnology approach that potentially could eliminate the problems of side effects and drug resistance in the treatment of cancer. Under traditional chemotherapy, cancer cells, like bacteria, can develop resistance to ...
Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer Friday, February 26, 2010 @ 3:18AMGenentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to ...
Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer Friday, February 26, 2010 @ 2:30AMGenentech, Inc., a wholly owned member of the Roche Group, recently announced that a Phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.
Study identifies risk factors for vitamin D deficiency in kidney disease patients on dialysis Friday, February 26, 2010 @ 1:19AMVitamin D deficiency is almost universal among kidney disease patients who have low blood protein levels and who start dialysis during the winter, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The research identifies a group of patients who are at extremely high risk of being deficient in vitamin D and provides some clues ...
Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis ... Thursday, February 25, 2010 @ 7:26AMAradigm Corporation (OTCBB:ARDM) (the "Company") announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis ...